Last $102.27 USD
Change Today +1.48 / 1.47%
Volume 9.7M
GILD On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
As of 4:00 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Robin L. Washington

Chief Financial Officer, Principal Accounting Officer and Executive Vice President, Gilead Sciences Inc.
AgeTotal Calculated CompensationThis person is connected to 24 board members in 3 different organizations across 7 different industries.

See Board Relationships
51$3,941,728
As of Fiscal Year 2013

Background*

Ms. Robin L. Washington is the Chief Financial Officer of Pharmasset, Inc. since January 17, 2012. Ms. Washington is the Chief Financial Officer of Gilead Sciences Inc. since May 5, 2008 and Executive Vice President since January 27, 2013. She serves as the Principal Accounting Officer of Gilead Sciences Inc. She is the Chief Financial officer and Senior Vice President at Gilead Palo Alto, Inc. Ms. Washington served as Senior Vice President at Gilead Sciences Inc. from ...

Read Full Background

Corporate Headquarters*

333 Lakeside Drive
Foster City, California 94404

United States

Phone: 650-574-3000
Fax: 650-578-9264

Board Members Memberships*

2005-2007
Former Independent Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
2008-2013
Former Director and Member of Audit & Corporate Governance Committee
2012-Present
Chief Financial Officer and Director
2013-Present
Independent Director
2013-Present
Director, Member of Audit Committee and Member of Retirement Plans Committee

Education*

BBA
University of Michigan
MBA
Pepperdine University

Other Affiliations*

Annual Compensation*

Salary$746,219
Total Annual Compensation$746,219

Stock Options*

Restricted Stock Awards$1,203,270
All Other Compensation$8,490
Exercised Options205,550
Exercised Options Value$5,272,609
Exercisable Options35,600
Exercisable Options Value$1,872,918
Unexercisable Options286,490
Unexercisable Options Value$13,410,432
Total Value of Options$20,555,958
Total Number of Options527,640

Total Compensation*

Total Annual Cash Compensation$1,542,209
Total Short Term Compensation$746,219
Other Long Term Compensation$1,211,760
Total Calculated Compensation$3,941,728
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GILD:US $102.27 USD +1.48

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Robert A. Bradway Chairman, Chief Executive Officer, President, Chairman of Executive Committee and Member of Equity Award Committee
Amgen Inc.
$1.5M
Lamberto Andreotti Chief Executive Officer, Director, Member of Executive Committee and Member of Securities Issuance Committee
Bristol-Myers Squibb Company
$1.7M
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.0M GBP
Richard A. Gonzalez Chairman, Chief Executive Officer and Chairman of Executive Committee
AbbVie Inc.
$1.5M
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GILEAD SCIENCES INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.